TRB Chemedica Int. SA

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

The French Ministry of Health granted partial reimbursement of VISMED^®, a sterile solution containing 0.18% sodium hyaluronate for ophthalmic use in the symptomatic treatment of ocular dryness. VISMED^® is the only sodium hyaluronate-based lubricant eye drops to be reimbursed in France.

Restoring Synovial Balance

OSTENIL® is a solution containing hyaluronic acid for injection into the joint cavity.

OSTENIL® is indicated for the treatment of symptoms of osteoarthritis. It has been shown to reduce pain and stiffness in the affected joint and to improve joint function.

A treatment cycle of 3 to 5 injections of OSTENIL® helps restore the normal balance between the breakdown and the production of hyaluronic acid in the affected joint. The net result is a decrease in joint pain and an improvement in joint function which may last for several months.

OSTENIL® is designed for long-term symptomatic relief in osteoarthritis.

pdf Prescribing information
Doctor information
Distributors
Contacts